Elevated Dehydroepiandrosterone Sulfate Levels as the Reproductive Phenotype in the Brothers of Women with Polycystic Ovary Syndrome

RICHARD S. LEGRO, ALLEN R. KUNSELMAN, LAWRENCE DEMERS, STEVE C. WANG, RHONDA BENTLEY-LEWIS, AND ANDREA DUNAIF

Division of Women's Health (R.B.-L., A.D.), Departments of Medicine and Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts 02115; Departments of Obstetrics and Gynecology (R.S.L.), Health Evaluation Sciences (A.R.K.), and Pathology (L.D.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Department of Statistics (S.C.W.), Harvard University, Cambridge, Massachusetts 02138

There is an inherited susceptibility to polycystic ovary syndrome (PCOS). Some investigators have suggested that premature male-pattern balding is a male phenotype in PCOS families, but this remains controversial. We recently reported evidence for an autosomal monogenic abnormality in ovarian and adrenal steroidogenesis in the sisters of women with PCOS. We performed this study to determine whether we could identify a clinical or biochemical phenotype in the brothers of women with PCOS. One hundred nineteen brothers of 87 unrelated women with PCOS and 68 age- and ethnicity-comparable unrelated control men were examined and had fasting blood samples obtained. The odds of balding (Hamilton score ≥ V) did not differ in the brothers of PCOS women compared with control men. Brothers of women with PCOS had significantly elevated dehydroepiandrosterone sulfate (DHEAS) levels [brothers 3035 ± 1132 ng/ml (mean ± SD) vs. control men 2494 ± 1172 ng/ml; \( P < 0.05 \)]. There was a significant positive linear relationship between DHEAS levels in PCOS probands and their brothers (\( r = 0.35; P = 0.001 \)). There was no significant bimodal distribution in DHEAS levels, and there were no significant differences in other parameters in brothers of PCOS women with high DHEAS levels compared with those with low DHEAS levels. There is familial clustering of elevated DHEAS levels in the brothers of women with PCOS, suggesting that this is a genetic trait. This might reflect the same underlying defect in steroidogenesis that we found in the sisters of women with PCOS. Balding was not increased in the brothers of women with PCOS. We conclude that there is a biochemical reproductive endocrine phenotype in men in PCOS families. (J Clin Endocrinol Metab 87: 2134–2138, 2002)

POLYCYSTIC OVARY SYNDROME (PCOS) is among the most common endocrinopathies of premenopausal women, affecting 5–10% of this population (1, 2). The syndrome is characterized by hyperandrogenism and chronic anovulation in the absence of specific disorders of the pituitary, ovaries, or adrenal glands (3). Familial aggregation of PCOS consistent with a genetic etiology has been well documented (4, 5). The male reproductive phenotypes that have been proposed in PCOS families include abnormalities in hair distribution, such as increased hair growth (6), and more commonly balding (7–10). This latter phenotype has been further refined to premature male balding defined as balding onset with an age of less than 30 yr (9, 10). Others have noted abnormalities in LH levels in male members of PCOS kindreds (11).

We recently reported elevated T and dehydroepiandrosterone levels in the sisters of women with PCOS (12). There was a bimodal distribution of biologically available T levels in these sisters consistent with a monogenic trait controlled by alleles of a gene at an autosomal locus (12). If there was variation in such a gene regulating steroidogenesis, it was our hypothesis that this should result in a reproductive phenotype in males in PCOS families. Previous studies have not systematically examined male relatives compared with a concurrently studied control group. We performed this study to determine whether we could identify a reproductive phenotype in the brothers of women with PCOS.

Subjects and Methods

Subjects

The brothers of 87 unrelated non-Hispanic white women with PCOS were studied. The diagnosis of PCOS was made in the proband by an elevation of circulating T and/or free and weakly bound T (uT) levels associated with chronic oligomenorrhea (no more than six menses per year) or amenorrhea (12). Women with nonclassical 21-hydroxylase deficiency, hyperprolactinemia, and androgen-secreting tumors were excluded by appropriate tests (12). The clinical features and reproductive hormone levels of the PCOS probands are summarized in Table 1 and have been reported previously in 18 of these women (12).

There were 156 brothers of the 87 women with PCOS, and 130 brothers were studied. Of the 26 brothers not willing to be studied, one family had four brothers, three families had two brothers, and 16 families had one brother. We limited the age range of brothers studied to 18–55 yr to control for age-related changes in reproductive hormone levels (13, 14). Eleven brothers were excluded because they were younger than 18 yr (n = 9) or older than 55 yr (n = 2). Accordingly, 119 brothers were included in the analysis. Of these 119 brothers, two families had four brothers, five had three brothers, 16 had two brothers, and 64 had a single brother.

Age-, weight-, and ethnicity-comparable unrelated control men (n = 68) without a history of hypertension or diabetes mellitus (either personally or in their first-degree relatives) were studied. Control men were in good health and, for at least 1 month before each study, were not

Abbreviations: BMI, Body mass index; DHEAS, dehydroepiandrosterone sulfate; PCOS, polycystic ovary syndrome; uT, free and weakly bound T.
TABLE 1. Clinical features and reproductive hormone levels in PCOS sisters

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean ± SD (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>29 ± 6 (87)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>35.6 ± 9.0 (87)</td>
</tr>
<tr>
<td>T (ng/dl)</td>
<td>79 ± 38 (87)</td>
</tr>
<tr>
<td>SHBG (nmol/liter)</td>
<td>61 ± 42 (78)</td>
</tr>
<tr>
<td>uT (ng/dl)</td>
<td>30 ± 24 (87)</td>
</tr>
<tr>
<td>DHEAS (ng/ml)</td>
<td>18 ± 22 (84)</td>
</tr>
<tr>
<td>LH (mIU/ml)</td>
<td>11 ± 9 (84)</td>
</tr>
</tbody>
</table>

To convert T and uT to nanomoles per liter, multiply by 0.03467; to convert DHEAS to micromoles per liter, multiply by 0.002714.

Clinical features (Tables 1 and 2)

The PCOS probands had elevated T, uT, and LH levels consistent with the biochemical profile of the disorder (2) (Table 1). PCOS probands were more obese (35.6 ± 9.0 kg/m²) than their brothers (29.2 ± 6.4 kg/m²). By design, brothers of PCOS women and control men were comparable in terms of BMI (Table 2). The brothers of PCOS women tended to be younger than the control men (P = 0.050). Accordingly, all analyses were adjusted for age to control for its potential confounding effect on outcome variables. There were no significant differences in waist to hip ratio or waist circumference in brothers of PCOS women compared with control men. There was no significant difference in blood pressure in brothers of PCOS women compared with control men. However, the odds of hypertension by Joint National Committee VI guidelines (16) (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) tended to be higher in PCOS brothers compared with control men, but this did not achieve statistical significance (adjusted odds ratio, 3.2; 95% confidence interval, 0.9, 10.7; P = 0.06). Balding (Hamilton score ≥ V) did not differ significantly in the brothers of PCOS women (5.5%) compared with control men (19%) (14, 15).

Biochemical features (Tables 3 and 4)

Circulating DHEAS levels were significantly higher in brothers of PCOS women than in control men (P = 0.02) (Fig. 1). Otherwise, there were no significant differences in circulating T, uT, SHBG, LH, or FSH levels in brothers of PCOS women compared with control men. In PCOS probands and
their brothers, the correlation between DHEAS levels was significant \( r = 0.35; P \leq 0.001 \) (Table 4). There were no other statistically significant correlations between the PCOS probands and their brothers. There was no significant bimodal distribution of DHEAS or other hormone levels in the brothers or in control men (Table 4). To further investigate whether we could use DHEAS levels to identify different subgroups of brothers, we compared brothers with DHEAS levels more than 1 sd below the mean with those with DHEAS levels more than 1 sd above the mean (i.e., mean – sd = 1322 ng/ml, and mean + sd = 3666 ng/ml). There were no significant differences in other outcome variables in these groups of brothers.

**TABLE 4. Linear correlation between PCOS brothers and their PCOS sisters**

<table>
<thead>
<tr>
<th>PCOS brother</th>
<th>PCOS proband</th>
<th>Pearson correlation coefficient ([P \text{ value}])</th>
<th>(n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHEAS</td>
<td>DHEAS</td>
<td>0.35 ([0.001])</td>
<td>85</td>
</tr>
<tr>
<td>T</td>
<td>T</td>
<td>-0.005 ([0.96])</td>
<td>86</td>
</tr>
<tr>
<td>uT</td>
<td>uT</td>
<td>-0.05 ([0.67])</td>
<td>86</td>
</tr>
<tr>
<td>LH</td>
<td>LH</td>
<td>0.06 ([0.62])</td>
<td>83</td>
</tr>
<tr>
<td>FSH</td>
<td>FSH</td>
<td>-0.02 ([0.83])</td>
<td>83</td>
</tr>
<tr>
<td>SHBG</td>
<td>SHBG</td>
<td>0.18 ([0.13])</td>
<td>70</td>
</tr>
</tbody>
</table>

Spearman correlation coefficient. \(n\), No. of family units.

**Discussion**

Our results suggest that there is a male biochemical reproductive phenotype in PCOS families. Circulating levels of the adrenal androgen DHEAS were significantly increased in brothers of PCOS women compared with control men. Furthermore, DHEAS levels in the brothers were significantly correlated with DHEAS levels in the PCOS probands, consistent with a heritable trait. There were no other significant changes in reproductive hormone levels in the brothers of women with PCOS compared with control men. There was no increase in the prevalence of balding in the brothers of PCOS women. Recently, we reported that hyperandrogenemia with or without menstrual irregularity appeared to be a genetic trait in the reproductive-age sisters of PCOS women (12). Another group has confirmed the high prevalence of hyperandrogenemia in PCOS female first-degree relatives (17).

The increased circulating T and DHEAS levels in affected sisters suggested a defect in a common factor regulating ovarian and adrenal androgen biosynthesis (12). Furthermore, we have found an association of this phenotype with candidate genes for PCOS in an affected sib pair analysis supporting our hypothesis that it had a genetic basis (18, 19). Elevated DHEAS levels in the brothers of PCOS women may reflect this steroidogenic defect (12). We did not find elevated T levels in brothers of PCOS women. This might be because T feeds back on the hypothalamic-pituitary axis to modulate its own secretion in men or because the substantially greater male T production rates made it difficult to discern subtle changes in circulating levels (20, 21). Alternatively, the varying ontogeny of the ovary and testes in PCOS families may obviate the potential abnormality in the testes and preserve it in the adrenal gland, which originates from a common anlage in both males and females.

A study of men with severe acne found significantly increased DHEAS levels (22). This supports the utility of this adrenal androgen as a marker for male hyperandrogenism.
We did not assess the presence of acne in this study. DHEAS is a good marker of abnormal steroidogenesis because of its lack of pulsatility and its long half life (23). DHEAS levels within an individual remain stable over time (24). There is a decline in circulating DHEAS levels with age (13, 14, 25), but this phenomenon was controlled for statistically in our analysis. Previous studies have suggested that there is a significant heritable component to circulating DHEAS levels in normal individuals (26–28). The heritability for DHEAS, however, has been found to be much less for men than for women (27), and heritability has also been noted to be stronger for T levels (26, 27, 29).

Premature male balding has been suggested to be a male phenotype in previous studies in PCOS families that ascertained the PCOS index case on the basis of ovarian morphology determined by ultrasonography rather than by endocrine criteria (6–10). No endocrinological marker of male affected status was noted. However, in one study, PCOS male relatives with premature balding had significantly higher total T levels than unaffected male relatives (10). There was no significant increase in DHEAS levels in those male relatives. Our sample size of PCOS brothers with balding was too small to test this hypothesis, but abnormalities in circulating T levels in male-pattern baldness are an infrequent finding (30, 31). Furthermore, control men tended to have more balding than the brothers of PCOS women. A survey of the U.S. male population age 18–49 yr reported high rates of significant male-pattern hair loss (32). The proportion of men with moderate to extensive hair loss increased with increasing age, ranging from 16% for men 18–29 yr of age to 53% of men 40–49 yr of age (32). We conclude that balding is extremely common in the U.S. male population and its prevalence is not increased in the brothers of PCOS women. Recent reports from investigators in the United Kingdom have also suggested that balding is not as reliable a male phenotype in PCOS families as they had originally reported (4).

In the sisters of women with PCOS, approximately 50% appear to have increased ovarian and adrenal steroidogenesis. If this is a monogenic trait, a similar number of brothers should be affected, although there might be sex-specific differences in penetrance (33, 34). However, there was no bimodal distribution of DHEAS levels in the brothers to suggest a monogenic trait (35) as we have found for T levels in the sisters of women with PCOS (12). This suggests a more complex pattern of inheritance for this phenotypic marker in familial PCOS. Individual DHEAS values in the brothers overlapped substantially with those in control men. Furthermore, there were no significant differences in other hormonal parameters in those brothers of PCOS women with high (> mean + 1 s.d) DHEAS levels compared with those with low (<1 s.d. + mean) DHEAS levels. Accordingly, it was not possible to assign affected status on the basis of a DHEAS value in a brother of a PCOS woman.

In summary, we have identified a male reproductive phenotype in the brothers of women with PCOS. This consists of elevations in circulating DHEAS levels. There was no increase in the prevalence of balding in this U.S. population of male first-degree relatives. DHEAS levels were highly correlated between brothers and their proband sisters, consistent with a heritable trait (26–28, 36). The same putative defect in steroidogenesis that we reported in the sisters of women with PCOS (12) could account for the observed DHEAS elevations in the brothers of PCOS probands.

Acknowledgments

We thank the nurses of the Pennsylvania State University College of Medicine and the Brigham and Women’s Hospital General Clinical Research Centers for their excellent care of the study participants; Ms. Sharon Ward for her superb coordination of the study; Drs. J.F. Strauss, R.S. Spielman, and M. Urbanek for critical review of the manuscript; and Ms. Ruth Capella for her skillful preparation of the manuscript.

Received October 2, 2001. Accepted December 22, 2001.

Address all correspondence and requests for reprints to: Richard S. Legro, M.D., Department of Obstetrics and Gynecology, 500 University Drive, Pennsylvania State University College of Medicine, M.S. Hershey Medical Center, Hershey, Pennsylvania 17033. E-mail: RSL1@psu.edu.

This work was supported by NIH Grant R01 DK 40605 (to A.D.), Grant K08 HD 0118 (to R.S.L.), The National Center for Infertility Research at University of Pennsylvania-Bingham and Women’s Hospital (to R.S.L.), and a grant from the University of California at San Francisco-Pennsylvania State University (to A.D.).

References


34. de Graaf J, Swinkels DW, de Haan AF, Demacker PN, Stalenhoef AF 1992 Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families. Am J Hum Genet 51:1295–1310


Second International Symposium on Progestins, Progesterone Receptor Modulators and Progesterone Antagonists
Siena, Italy
November 20–23, 2002
www.unisi.it/eventi/progestins

Topics to be reviewed include: Mechanism of Action, Progesterone Receptors and their Isoforms, Pharmacology, Target Tissue Effects, Clinical Applications, Contraception, Controversial Issues Related to Progestin Treatment.

For more information, contact Tzina Lindenberg, E-mail: hormones@netmedia.net.il, Fax 972-2-6522018, Tel 972-2-6555188.